BRPI0511753A - formulação de irinotecano e respectiva composição farmacêutica - Google Patents

formulação de irinotecano e respectiva composição farmacêutica

Info

Publication number
BRPI0511753A
BRPI0511753A BRPI0511753-4A BRPI0511753A BRPI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A BR PI0511753 A BRPI0511753 A BR PI0511753A
Authority
BR
Brazil
Prior art keywords
irinotecan
formulation
mol
liposome
pharmaceutical composition
Prior art date
Application number
BRPI0511753-4A
Other languages
English (en)
Inventor
Keisuke Yoshino
Shigenori Nozawa
Masashi Isozaki
Seigo Sawada
Ikuo Kato
Takeshi Matsuzaki
Original Assignee
Terumo Corp
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp, Yakult Honsha Kk filed Critical Terumo Corp
Publication of BRPI0511753A publication Critical patent/BRPI0511753A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçãO DE IRINOTECANO E RESPECTIVA COMPOSIçãO FARMACêUTICA. A presente invenção refere-se a uma formulação de irinotecano capaz de suportar o irinotecano e/ou um sal do mesmo em um veículo de vesícula fechada, em uma alta concentração, e existindo no sangue por um período longo de tempo pela retentividade dramaticamente aperfeiçoada no sangue, comparada a uma formulação de lipossomo de irinotecano convencionalmente conhecida. Ou seja, uma formulação de irinotecano que inclui uma vesícula fechada formada por uma membrana lipídica, em que o irinotecano e/ou um sal do mesmo é encapsulado em uma concentração de pelo menos 0,07 mol/mol (mol de fármaco/mol de lipídios totais da membrana). Há um gradiente iónico entre uma fase aquosa interna e uma fase aquosa externa na formulação de irinotecano. A vesícula fechada é preferivelmente o lipossomo, em que somente a superfície externa do lipossomo é preferivelmente modificada com um agente modificador da superfície contendo um polímero hidrofílico.
BRPI0511753-4A 2004-06-01 2005-05-31 formulação de irinotecano e respectiva composição farmacêutica BRPI0511753A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01
PCT/JP2005/009953 WO2005117878A1 (ja) 2004-06-01 2005-05-31 イリノテカン製剤

Publications (1)

Publication Number Publication Date
BRPI0511753A true BRPI0511753A (pt) 2008-01-02

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511753-4A BRPI0511753A (pt) 2004-06-01 2005-05-31 formulação de irinotecano e respectiva composição farmacêutica

Country Status (24)

Country Link
US (1) US7846473B2 (pt)
EP (1) EP1752150B1 (pt)
JP (1) JP4885715B2 (pt)
KR (1) KR100889139B1 (pt)
CN (1) CN1960729B (pt)
AP (1) AP2255A (pt)
AR (1) AR049137A1 (pt)
AU (1) AU2005249314B2 (pt)
BR (1) BRPI0511753A (pt)
CA (1) CA2567857C (pt)
CR (1) CR8768A (pt)
EA (1) EA011612B1 (pt)
EC (1) ECSP067041A (pt)
ES (1) ES2594621T3 (pt)
GE (1) GEP20094620B (pt)
IL (1) IL179558A0 (pt)
MX (1) MXPA06013874A (pt)
NO (1) NO20066074L (pt)
NZ (1) NZ551748A (pt)
TN (1) TNSN06395A1 (pt)
TW (1) TWI362931B (pt)
UA (1) UA85099C2 (pt)
WO (1) WO2005117878A1 (pt)
ZA (1) ZA200610204B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1746976T3 (pl) 2004-05-03 2017-09-29 Merrimack Pharmaceuticals, Inc. Liposomy przydatne w systemie podawania leków
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
CA2724408A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
WO2010058840A1 (ja) * 2008-11-20 2010-05-27 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
EP2508170B1 (en) * 2009-12-03 2015-07-29 Jiangsu Hengrui Medicine Co., Ltd. Liposome of irinotecan or its hydrochloride and preparation method thereof
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
AU2012332176B2 (en) 2011-11-03 2016-03-10 Tlc Biopharmaceuticals, Inc. Pharmaceutical compositions of hydrophobic camptothecin derivatives
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) * 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
SG10201912568PA (en) 2015-10-16 2020-02-27 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
SG11201903615WA (en) * 2016-11-02 2019-05-30 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
CA3231432A1 (en) * 2021-10-15 2023-04-20 Tianyi Ke Composition containing antitumor drug, and preparation method therefor and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
DK1121102T3 (da) * 1998-09-16 2003-08-11 Alza Corp Liposomindesluttede topoisomeraseinhibitorer
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
DE60042159D1 (en) * 1999-06-25 2009-06-18 Terumo Corp Liposome
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
MXPA02012817A (es) * 2000-06-30 2004-07-30 Inex Pharmaceuticals Inc Drogas antineoplasicas liposomales y uso de las mismas.
EP1432402B1 (en) 2001-10-03 2006-11-22 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2003028697A2 (en) * 2001-10-03 2003-04-10 Celator Technologies Inc. Liposome loading with metal ions
EP1443900B1 (en) * 2001-11-13 2012-05-23 Celator Pharmaceuticals, Inc. Lipid carrier compositions with enhanced blood stability
ATE373466T1 (de) 2001-11-13 2007-10-15 Celator Pharmaceuticals Inc Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
CA2527130A1 (en) * 2003-04-02 2004-10-14 Paul Tardi Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
PL1746976T3 (pl) * 2004-05-03 2017-09-29 Merrimack Pharmaceuticals, Inc. Liposomy przydatne w systemie podawania leków
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain

Also Published As

Publication number Publication date
AP2255A (en) 2011-07-21
EA200602246A1 (ru) 2007-04-27
TNSN06395A1 (en) 2008-02-22
US20080069868A1 (en) 2008-03-20
UA85099C2 (en) 2008-12-25
JP4885715B2 (ja) 2012-02-29
NO20066074L (no) 2007-02-28
AP2006003837A0 (en) 2006-12-31
JPWO2005117878A1 (ja) 2008-04-03
EA011612B1 (ru) 2009-04-28
US7846473B2 (en) 2010-12-07
EP1752150B1 (en) 2016-08-31
CR8768A (es) 2007-08-28
EP1752150A1 (en) 2007-02-14
WO2005117878A1 (ja) 2005-12-15
NZ551748A (en) 2010-02-26
CA2567857A1 (en) 2005-12-15
CN1960729B (zh) 2012-04-11
AU2005249314B2 (en) 2008-09-11
ZA200610204B (en) 2008-01-30
KR100889139B1 (ko) 2009-03-17
CA2567857C (en) 2009-12-22
MXPA06013874A (es) 2007-04-25
CN1960729A (zh) 2007-05-09
IL179558A0 (en) 2007-07-04
KR20070037440A (ko) 2007-04-04
ECSP067041A (es) 2006-12-29
AU2005249314A1 (en) 2005-12-15
EP1752150A4 (en) 2012-06-20
AR049137A1 (es) 2006-06-28
ES2594621T3 (es) 2016-12-21
GEP20094620B (en) 2009-02-25
TWI362931B (en) 2012-05-01
TW200600095A (en) 2006-01-01

Similar Documents

Publication Publication Date Title
BRPI0511753A (pt) formulação de irinotecano e respectiva composição farmacêutica
Sundin et al. Gentamicin inhibits renal protein and phospholipid metabolism in rats: implications involving intracellular trafficking
Grijalba et al. Ca2+-induced increased lipid packing and domain formation in submitochondrial particles. A possible early step in the mechanism of Ca2+-stimulated generation of reactive oxygen species by the respiratory chain
Stefanovic et al. α‐Synuclein oligomers distinctively permeabilize complex model membranes
US4921644A (en) Mucin directed lipsome
CN101039689B (zh) 用于上皮相关病症的局部组合物和方法
Pata et al. Membrane solubilization by detergent: resistance conferred by thickness
Alarcón et al. Ion channel formation by Alzheimer's disease amyloid β-peptide (Aβ40) in unilamellar liposomes is determined by anionic phospholipids
Jaremko et al. Accelerated hemolysis and neurotoxicity in neuron‐glia‐blood clot co‐cultures
Ježek et al. A structure–activity study of fatty acid interaction with mitochondrial uncoupling protein
Dong et al. Protective effect of HIF-1α against hippocampal apoptosis and cognitive dysfunction in an experimental rat model of subarachnoid hemorrhage
Liu et al. Antimicrobial tissue concentrations
Mingeot‐Leclercq et al. Molecular parameters involved in aminoglycoside nephrotoxicity
Ostroumova et al. The interaction of dipole modifiers with amphotericin-ergosterol complexes. Effects of phospholipid and sphingolipid membrane composition
BRPI0416650A (pt) composição de lipossoma estável para a aplicação de um agente farmacêutico, composição de lipossoma estéril e estável para a aplicação de um agente farmacêutico método para a produção de uma composição de lipossoma estável para a aplicação de um agente farmacêutico, composição farmacêutica, uso de uma composição de lipossoma, dispositivo para conter uma composição de lipossoma estável, kit para a aplicação de um agente farmacêutico a um paciente, método para aumentar a estabilidade de composições de lipossomas, método para a identificação de uma composição de lipossoma estável na fase, composição de lipossoma e composição de lipossoma estável na fase
Yildiz et al. The protective role of fosfomycin in lung injury due to oxidative stress and inflammation caused by sepsis
Romero et al. Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes
Fabrizio et al. In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: the enhancing effect of potassium sorbate
Fait et al. Volume expansion of erythrocytes is not the only mechanism responsible for the protection by arginine-based surfactants against hypotonic hemolysis
Tuneva et al. Effect of NMDA on production of reactive oxygen species by human lymphocytes
Steinberg et al. Sustained‐release delivery systems of triclosan for treatment of Streptococcus mutans biofilm
Shimizu et al. pH switching that crosses over the isoelectric point (pI) can improve the entrapment of proteins within giant liposomes by enhancing protein–membrane interaction
Tjong et al. Role of glycosphingolipid conformational change in membrane pore forming activity of cobra cardiotoxin
Bartkowiak et al. Study of mucin interaction with model phospholipid membrane at the air–water interface
Sadzuka et al. Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.